Operating Expenses Summary of Biotest Aktiengesellschaft

Biotest Aktiengesellschaft's latest annual operating expenses in 2023 was 136.8 Million EUR , up 6.22% from previous year.
Biotest Aktiengesellschaft's latest quarterly operating expenses in 2024 Q2 was 35.6 Million EUR , down -33.25% from previous quarter.
Biotest Aktiengesellschaft reported a annual operating expenses of 133.4 Million EUR in annual operating expenses 2022, up 0.45% from previous year.
Biotest Aktiengesellschaft reported a annual operating expenses of 132.8 Million EUR in annual operating expenses 2021, up 0.15% from previous year.
Biotest Aktiengesellschaft reported a quarterly operating expenses of 35.6 Million EUR for 2024 Q2, down -33.25% from previous quarter.
Biotest Aktiengesellschaft reported a quarterly operating expenses of 33.1 Million EUR for 2023 Q3, up 75.13% from previous quarter.

Annual Operating Expenses Chart of Biotest Aktiengesellschaft (2023 - 2002)

Historical Annual Operating Expenses of Biotest Aktiengesellschaft (2023 - 2002)

Year	Operating Expenses	Operating Expenses Growth
2023	136.8 Million EUR	6.22%
2022	133.4 Million EUR	0.45%
2021	132.8 Million EUR	0.15%
2020	132.6 Million EUR	-2.14%
2019	135.5 Million EUR	2.42%
2018	132.3 Million EUR	-15.63%
2017	156.8 Million EUR	14.04%
2016	137.5 Million EUR	-35.39%
2015	212.8 Million EUR	24.15%
2014	171.4 Million EUR	8.96%
2013	157.3 Million EUR	16.57%
2012	134.94 Million EUR	6.93%
2011	126.2 Million EUR	3.79%
2010	121.58 Million EUR	-19.4%
2009	150.84 Million EUR	-7.74%
2008	163.49 Million EUR	253.4%
2007	-106.58 Million EUR	-19.23%
2006	-89.39 Million EUR	-24.57%
2005	-71.76 Million EUR	-184.33%
2004	85.1 Million EUR	-5.28%
2003	89.84 Million EUR	-17.58%
2002	109 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	38.2 Million EUR	-12.18%
2024 Q2	35.6 Million EUR	-33.25%
2023 Q3	33.1 Million EUR	75.13%
2023 Q1	33.8 Million EUR	-20.66%
2023 Q2	18.9 Million EUR	-44.08%
2023 Q4	43.5 Million EUR	31.42%
2023 FY	141.7 Million EUR	6.22%
2022 Q4	42.6 Million EUR	36.98%
2022 Q3	31.1 Million EUR	-11.14%
2022 Q2	35 Million EUR	12.18%
2022 Q1	31.2 Million EUR	-21.61%
2022 FY	133.4 Million EUR	0.45%
2021 FY	132.8 Million EUR	0.15%
2021 Q1	32.3 Million EUR	-9.01%
2021 Q2	32.4 Million EUR	0.31%
2021 Q3	28.4 Million EUR	-12.35%
2021 Q4	39.8 Million EUR	40.14%
2020 FY	132.6 Million EUR	-2.14%
2020 Q1	27.1 Million EUR	-41.21%
2020 Q2	38 Million EUR	40.22%
2020 Q3	32 Million EUR	-15.79%
2020 Q4	35.5 Million EUR	10.94%
2019 Q1	29 Million EUR	-26.4%
2019 Q3	31.7 Million EUR	10.45%
2019 Q4	46.1 Million EUR	45.43%
2019 FY	135.5 Million EUR	2.42%
2019 Q2	28.7 Million EUR	-1.03%
2018 Q2	30.4 Million EUR	-7.88%
2018 FY	132.3 Million EUR	-15.63%
2018 Q1	33 Million EUR	-15.17%
2018 Q3	29.6 Million EUR	-2.63%
2018 Q4	39.4 Million EUR	33.11%
2017 Q3	37.1 Million EUR	-15.87%
2017 Q2	44.1 Million EUR	20.16%
2017 FY	156.8 Million EUR	14.04%
2017 Q4	38.9 Million EUR	4.85%
2017 Q1	36.7 Million EUR	22.33%
2016 Q4	30 Million EUR	-4.15%
2016 Q2	38.8 Million EUR	3.74%
2016 Q1	37.4 Million EUR	-34.73%
2016 FY	137.5 Million EUR	-35.39%
2016 Q3	31.3 Million EUR	-19.33%
2015 FY	212.8 Million EUR	24.15%
2015 Q3	65.1 Million EUR	41.21%
2015 Q4	57.3 Million EUR	-11.98%
2015 Q2	46.1 Million EUR	4.06%
2015 Q1	44.3 Million EUR	4.98%
2014 Q4	42.2 Million EUR	-7.66%
2014 FY	171.4 Million EUR	8.96%
2014 Q1	40.5 Million EUR	-6.03%
2014 Q2	43 Million EUR	6.17%
2014 Q3	45.7 Million EUR	6.28%
2013 Q3	37.5 Million EUR	-4.09%
2013 FY	157.3 Million EUR	16.57%
2013 Q1	37.6 Million EUR	14.84%
2013 Q2	39.1 Million EUR	3.99%
2013 Q4	43.1 Million EUR	14.93%
2012 Q4	32.74 Million EUR	3.29%
2012 FY	134.94 Million EUR	6.93%
2012 Q1	37 Million EUR	9.14%
2012 Q2	33.5 Million EUR	-9.46%
2012 Q3	31.7 Million EUR	-5.37%
2011 FY	126.2 Million EUR	3.79%
2011 Q4	33.9 Million EUR	9.36%
2011 Q1	29.4 Million EUR	89.81%
2011 Q3	31 Million EUR	-2.82%
2011 Q2	31.9 Million EUR	8.5%
2010 Q4	15.48 Million EUR	-51.14%
2010 Q3	31.7 Million EUR	-8.12%
2010 Q2	34.5 Million EUR	-13.53%
2010 FY	121.58 Million EUR	-19.4%
2010 Q1	39.9 Million EUR	2.18%
2009 Q4	39.04 Million EUR	12.86%
2009 FY	150.84 Million EUR	-7.74%
2009 Q2	38.4 Million EUR	-1.03%
2009 Q1	38.8 Million EUR	0.0%
2009 Q3	34.6 Million EUR	-9.9%
2008 FY	163.49 Million EUR	253.4%
2007 FY	-106.58 Million EUR	-19.23%
2006 FY	-89.39 Million EUR	-24.57%
2005 FY	-71.76 Million EUR	-184.33%
2004 FY	85.1 Million EUR	-5.28%
2003 FY	89.84 Million EUR	-17.58%
2002 FY	109 Million EUR	0.0%

Peer Operating Expenses Comparison of Biotest Aktiengesellschaft

Name	Operating Expenses	Operating Expenses Difference
BioNTech SE	2.52 Billion EUR	94.59%
CureVac N.V.	211.75 Million EUR	35.397%
Biotest Aktiengesellschaft	136.8 Million EUR	0.0%
BRAIN Biotech AG	24.94 Million EUR	-448.494%
Formycon AG	23.73 Million EUR	-476.413%
Heidelberg Pharma AG	27.81 Million EUR	-391.805%
Medigene AG	20.54 Million EUR	-566.018%

Global Stocks Search

Biotest Aktiengesellschaft (BIO.DE)

Operating Expenses Summary of Biotest Aktiengesellschaft

Annual Operating Expenses Chart of Biotest Aktiengesellschaft (2023 - 2002)

Historical Annual Operating Expenses of Biotest Aktiengesellschaft (2023 - 2002)

Peer Operating Expenses Comparison of Biotest Aktiengesellschaft